Related references
Note: Only part of the references are listed.Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection
Soji Shimomura et al.
HEPATOLOGY RESEARCH (2012)
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
Hiromitsu Kumada et al.
JOURNAL OF HEPATOLOGY (2012)
Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy
Tsugiko Oze et al.
JOURNAL OF HEPATOLOGY (2011)
Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response
Peter Ferenci et al.
GASTROENTEROLOGY (2010)
Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
Maria Buti et al.
HEPATOLOGY (2010)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis
Mika Kurokawa et al.
HEPATOLOGY RESEARCH (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
Alessandra Mangia et al.
HEPATOLOGY (2008)
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders
Brian L. Pearlman et al.
HEPATOLOGY (2007)
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
Jian-Wu Yu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
Jose M. Sanchez-Tapias et al.
GASTROENTEROLOGY (2006)
Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis
C. -H. Hung et al.
JOURNAL OF VIRAL HEPATITIS (2006)
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
Gregory L. Armstrong et al.
ANNALS OF INTERNAL MEDICINE (2006)
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
DM Jensen et al.
HEPATOLOGY (2006)
Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
T Berg et al.
GASTROENTEROLOGY (2006)
Antiviral therapy for chronic hepatitis C: past, present, and future
N Hayashi et al.
JOURNAL OF GASTROENTEROLOGY (2006)
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
P Ferenci et al.
JOURNAL OF HEPATOLOGY (2005)
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
N Akuta et al.
INTERVIROLOGY (2005)
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response
T Carlsson et al.
JOURNAL OF VIRAL HEPATITIS (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death
A Kasahara et al.
JOURNAL OF VIRAL HEPATITIS (2004)
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
S Zeuzem et al.
JOURNAL OF HEPATOLOGY (2004)
Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response
Y Imai et al.
JOURNAL OF GASTROENTEROLOGY (2004)
Standardized reporting of clinical practice guidelines: A proposal from the conference on guideline standardization
RN Shiffman et al.
ANNALS OF INTERNAL MEDICINE (2003)
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
GL Davis et al.
HEPATOLOGY (2003)
Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy
T Berg et al.
HEPATOLOGY (2003)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
Y Shiratori et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
